-
Concept Medical announces first patient enrolment in MAGICAL-SV IDE Trial
04 Aug 2025 16:35 GMT
… the treatment of Coronary Artery Lesions in Small Vessels) trial. Investigational … Medical is now actively enrolling in three Investigational Device Exemption (IDE) trials … Concept Medical’s MagicTouch Sirolimus-Coated Balloon (SCB) to Drug-Eluting Stents …
-
First Patient Enrolled In Bold New Trial Targeting Safer, Implant-Free Heart Treatments
04 Aug 2025 15:49 GMT
… the FDA’s IDE approval of Concept Medical’s … Medical is now actively enrolling in three IDE trials … trial (2:1 randomisation) comparing Concept Medical’s MagicTouch sirolimus-coated balloon to drug … [ZES]) for the treatment of small coronary artery …
-
Concept Medical Announces First Patient Enrollment In MAGICAL-SV IDE Trial, Expanding Its Coronary Clinical Program Across The US And Europe
04 Aug 2025 10:36 GMT
… the FDA’s IDE approval of Concept Medical’s … Medical is now actively enrolling in three IDE trials … trial (2:1 randomization) comparing Concept Medical’s MagicTouch sirolimus-coated balloon to drug … [ZES]) for the treatment of small coronary artery …
-
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
04 Aug 2025 07:21 GMT
… the FDA’s IDE approval of Concept Medical’s … Medical is now actively enrolling in three IDE trials … trial (2:1 randomization) comparing Concept Medical’s MagicTouch sirolimus-coated balloon to drug … [ZES]) for the treatment of small coronary artery …
-
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
05 Aug 2025 11:00 GMT
… AVIM”) therapy and Virtue Sirolimus AngioInfusion Balloon (“SAB”) … non-dilutive investments from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND, … collaborations with leading medical device companies to … by the FDA for the treatment of uncontrolled …
-
Orchestra BioMed Announces Pricing of $40 Million Public Offering
01 Aug 2025 11:59 GMT
… Sirolimus AngioInfusion Balloon (“SAB”) program and the planned Virtue SAB trial … for the treatment of atherosclerotic artery … medical technology, for development and commercialization of Virtue SAB for the treatment … . Food and Drug Administration across these …
-
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
31 Jul 2025 20:01 GMT
… diversified portfolio of biotech and pharmaceutical product revenue streams … collaborations with leading medical device companies to … Designation by the FDA for the treatment of uncontrolled … extended-release formulation of sirolimus, SirolimusEFR™ through a …
-
Orchestra BioMed Announces Proposed Public Offering
31 Jul 2025 20:02 GMT
… Sirolimus AngioInfusion Balloon (“SAB”) program and the planned Virtue SAB trial … for the treatment of atherosclerotic artery … medical technology, for development and commercialization of Virtue SAB for the treatment … . Food and Drug Administration across these …
-
Orchestra BioMed prices $40M offering, amends Medtronic deal
01 Aug 2025 14:50 GMT
… its Virtue sirolimus angioinfusion balloon program and a planned clinical trial. Other … partnerships. It partnered with Ligand Pharmaceuticals and Medtronic, simultaneously announcing the … to see OBIO add Ligand Pharmaceuticals as a new strategic partner …
-
Dr Riedel on the Role of the Multidisciplinary Team in PEComa Management
01 Aug 2025 03:55 GMT
… professor of medicine in the Department of Medicine at the Duke … University School of Medicine, as well as a … he emphasized. In addition, medical oncologists with specific expertise in … of the availability of nab-sirolimus (Fyarro), the agent approved …
About
© 1995-2025